Aurora Cannabis Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY Revenue (est.)
$207.5Mnext fiscal year
FY EPS (est.)
-$0.12next fiscal year
Monitoring Framework
Key Performance Indicators
Global Medical Cannabis Net Revenue Quarterly288.6MTarget: Offset Canadian medical reimbursement declines through international growth
Adjusted EBITDA Quarterly53.8MTarget: Maintain positive adjusted EBITDA, though projected lower year-over-year in FY2027
Adjusted Gross Margin Quarterly6,400.0%Target: Mid-to-high 50s for FY2027
Watch Items
- Canadian Medical Reimbursement Rate ReductionsTrigger: 30% reduction in government reimbursed pricing effective April 1, 2026Action: Invest in international sales initiatives and expand EU-GMP capacity to offset domestic margin compression.
- International Market Expansion (Germany and Poland)Trigger: Regulatory changes affecting prescription volumes or market accessAction: Leverage the newly acquired Safari Flower Company facility to scale EU-GMP certified supply.
Research as of 20 Jun 2026